Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd.
Your view on KNSA
Overview
What the company does, where it operates, and who runs it.
About Kiniksa Pharmaceuticals, Ltd.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Sanj K. Patel
- Headquarters
- Clarendon House, Hamilton, BM
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Sanj K. Patel
- Headquarters
- Clarendon House, Hamilton, BM
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Kiniksa Pharmaceuticals, Ltd., and the rating behind it. KNSA last traded at $72.98, 67.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Kiniksa Pharmaceuticals, Ltd.. Starting points for Kiniksa Pharmaceuticals, Ltd.: P/E 67.0, EPS $1.04, beta 0.09 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Kiniksa Pharmaceuticals, Ltd.. Kiniksa Pharmaceuticals, Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Kiniksa Pharmaceuticals, Ltd.. Trailing twelve-month EPS for Kiniksa Pharmaceuticals, Ltd. stands at $1.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Kiniksa Pharmaceuticals, Ltd.. Kiniksa Pharmaceuticals, Ltd. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Kiniksa Pharmaceuticals, Ltd. valued side by side against its closest peers. Kiniksa Pharmaceuticals, Ltd. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Kiniksa Pharmaceuticals, Ltd., and how their positions are changing. At a $5.69B market value, institutional positions materially move Kiniksa Pharmaceuticals, Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Kiniksa Pharmaceuticals, Ltd. executives and directors. Shares of Kiniksa Pharmaceuticals, Ltd. have traded between $17.82 and $42.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Kiniksa Pharmaceuticals, Ltd.. Kiniksa Pharmaceuticals, Ltd. is a $5.69B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Kiniksa Pharmaceuticals, Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Kiniksa Pharmaceuticals, Ltd.. Coverage tracks Kiniksa Pharmaceuticals, Ltd. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.